OTCPK:KLYG

Stock Analysis Report

Executive Summary

Kelyniam Global, Inc., a medical device manufacturing company, produces custom prosthetics utilizing computer aided design and manufacturing of medical grade polymers.

Snowflake

Fundamentals

Imperfect balance sheet and overvalued.

Share Price & News

How has Kelyniam Global's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.5%

KLYG

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

n/a

KLYG

15.6%

US Medical Equipment

6.9%

US Market

Return vs Industry: Insufficient data to determine how KLYG performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how KLYG performed against the US Market.


Shareholder returns

KLYGIndustryMarket
7 Day-4.5%1.9%0.4%
30 Day-41.7%-1.7%-1.1%
90 Dayn/a-0.03%-0.5%
1 Yearn/a16.5%15.6%9.3%6.9%
3 Year110.0%110.0%72.1%66.9%45.8%36.4%
5 Year-56.3%-56.3%125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is Kelyniam Global's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kelyniam Global undervalued compared to its fair value and its price relative to the market?

2.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate KLYG's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate KLYG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KLYG is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: KLYG is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate KLYG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KLYG is good value based on its PB Ratio (2.2x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Kelyniam Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kelyniam Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of KLYG’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Kelyniam Global's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Kelyniam Global performed over the past 5 years?

-48.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: KLYG is unprofitable, and losses have increased over the past 5 years at a rate of -48.1% per year.

Accelerating Growth: Unable to compare KLYG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KLYG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: KLYG has a negative Return on Equity (-2.53%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: KLYG is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: KLYG is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Kelyniam Global's financial position?


Financial Position Analysis

Short Term Liabilities: KLYG's short term assets ($407.8K) do not cover its short term liabilities ($430.0K)

Long Term Liabilities: KLYG's short term assets (407.8K) exceeds its long term liabilities (219.2K)


Debt to Equity History and Analysis

Debt Level: KLYG's debt to equity ratio (70.4%) is considered high

Reducing Debt: KLYG's debt to equity ratio has reduced from 71.5% to 70.4% over the past 5 years.


Balance Sheet

Inventory Level: KLYG has a high level of physical assets or inventory.

Debt Coverage by Assets: KLYG's debt is not covered by short term assets (assets are 1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if KLYG has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if KLYG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Kelyniam Global's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate KLYG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KLYG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if KLYG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KLYG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KLYG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Kelyniam Global's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Ross Bjella (57yo)

1.8yrs

Tenure

0

Mr. Ross Bjella has been the Chairman and Chief Executive Officer of Kelyniam Global Inc. since January 2018. He previously worked for Kelyniam as a consultant and was instrumental in helping the company r ...


Management Age and Tenure

1.8yrs

Average Tenure

Experienced Management: KLYG's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Christopher Breault

    COO & Director

    • Tenure: 0yrs
  • Christopher Mirucki

    Chief Medical Officer

    • Tenure: 0yrs
  • Michael Hamblett

    Director of Investor Relations

    • Tenure: 0yrs
  • Mark Smith

    VP of Sales & Business Development and Director

    • Tenure: 5.3yrs
  • Ross Bjella (57yo)

    Chairman & CEO

    • Tenure: 1.8yrs

Board Members

  • Christopher Breault

    COO & Director

    • Tenure: 0yrs
  • Mark Smith

    VP of Sales & Business Development and Director

    • Tenure: 5.3yrs
  • Ross Bjella (57yo)

    Chairman & CEO

    • Tenure: 1.8yrs

Company Information

Kelyniam Global, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kelyniam Global, Inc.
  • Ticker: KLYG
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.351m
  • Shares outstanding: 25.73m
  • Website: https://www.kelyniam.com

Location

  • Kelyniam Global, Inc.
  • 97 River Road
  • Suite A
  • Collinsville
  • Connecticut
  • 6019
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KLYGOTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 2008

Biography

Kelyniam Global, Inc., a medical device manufacturing company, produces custom prosthetics utilizing computer aided design and manufacturing of medical grade polymers. It offers cranial and craniofacial im ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:01
End of Day Share Price2019/10/17 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.